Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
2022 · The Lancet. Gastroenterology & hepatology · 115 citations
https://doi.org/10.1016/s2468-1253(22)00335-1